Therefore, to mitigate the risk of VAU as an adverse effect of COVID-19 vaccination, it is advisable for patients slated for anti-VEGF intravitreal injections to have completed their COVID-19 vaccination at least two weeks prior. This evidence concerns the gene VEGFA and COVID-19.